Search

Displaying results 3371 - 3380 of 9322 in total
  1. Drug

    Nesiritide

    go.drugbank.com/drugs/DB04899
    ApprovedInvestigationalWithdrawn

    Nesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing).

  2. Drug

    Obecabtagene autoleucel

    go.drugbank.com/drugs/DB17362
    ApprovedInvestigational

    [A265050] On November 8, 2024, obecabtagene autoleucel was approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia. … Obecabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with a fast off-rate binding profile for CD19.

    Synonyms: SELF-INACTIVATING LENTIVIRAL VECTOR CONSISTING OF 5' FUSION BETWEEN THE CMV PROMOTER AND HIV LTR, WHERE THE CMV PROMOTER REPLACES THE U3 REGION., PACKAGING SIGNAL (.PSI.), THE REV RESPONSIVE ELEMENT (RRE) AND THE CENTRAL POLYPURINE TRACT (CPPT) ARE RETAINCategories: Genetically-modified Autologous T Cells, CD19-Directed Genetically Modified Autologous T-cell Immunotherapies
  3. Drug

    Dapiprazole

    go.drugbank.com/drugs/DB00298
    Approved

    It is found in ophthalmic solutions used to reverse mydriasis after an eye examination.

  4. Drug

    Protein S human

    go.drugbank.com/drugs/DB13149
    ApprovedInvestigational

    It serves as a negative feedback mechanism in the coagulation cascade.

  5. Drug

    Zolasartan

    go.drugbank.com/drugs/DB20140
    Experimental

    The usage of the INN stem '-sartan' in the name indicates that Zolasartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).

    Categories: Agents Acting on the Renin-Angiotensin System
  6. Drug

    Tildrakizumab

    go.drugbank.com/drugs/DB14004
    ApprovedInvestigational

    The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy … A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects [A32257].

  7. Drug

    Paricalcitol

    go.drugbank.com/drugs/DB00910
    ApprovedInvestigational

    Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

  8. Drug

    VidPrevtyn Beta

    go.drugbank.com/drugs/DB16427
    Approved

    [A245829,L49696] In October 2022, VidPrevtyn Beta was approved in the European Union for use as a booster dose in patients who have previously received a COVID-19 vaccine.[L49691] … comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from Sf9 cells of the

    Synonyms: SARS-CoV-2 prefusion Spike delta TM protein, recombinant (B.1.351 strain)
  9. Drug

    Phosphocreatine

    go.drugbank.com/drugs/DB13191
    InvestigationalNutraceutical

    Phosphocreatine - or creatine phosphate - is the phosphorylated form of creatine. … It is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical role as a rapidly acting energy buffer for muscle cell actions like contractions via its ability to

  10. Drug

    Ethoheptazine

    go.drugbank.com/drugs/DB08988
    ApprovedWithdrawn

    Ethoheptazine is marketed under the name Zactane. It is a phenazepine based opioid analgesic. It was invented in the 1950s and is related to other drugs such as proheptazine. … Ethoheptazine is no longer marketed in the United States.